双重向p53和c-MYC可以选择性地消除白血病干细胞
Sheela A Abraham1, Lisa E M Hopcroft1, Emma Carrick2,3
1Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, UK.
针对p53和c- MYC而不是BCR- ABL,可以消除慢性髓性白血病 (CML) 的白血病干细胞 (LSC). 这种精准医疗方法可以消除LSC,同时保留正常干细胞,
科学领域:
- 血液学
- 癌症学
- 分子生物学
背景情况:
- 慢性髓性白血病 (CML) 源于白血病干细胞 (LSCs),这些干细胞没有被当前的BCR-ABL激酶抑制剂消除.
- 由于酶独立的生存途径,LSCs持续存在,因此需要新的治疗点.
研究的目的:
- 识别和向对于CML中LSC存活至关重要的激酶独立途径.
- 研究p53和c-MYC在LSC调节中的作用,并探索它们的治疗潜力.
主要方法:
- 用蛋白质组学,转录组学和网络分析来研究来自CML患者的人类LSCs.
- 进行了p53和c- MYC通路的干扰,以评估它们对LSC的影响.
- 在小鼠体内进行了研究,以评估向这些途径的有效性.
主要成果:
- 不管对伊马替尼的反应如何,LSC中异常表达的蛋白与p53和c- MYC共同调节.
- 同时扰乱p53和c-MYC诱导的协同细胞杀死和LSC的分化.
- 向p53和c-MYC导致小鼠几乎消除了可移植的人类LSC,并保留了正常的造血干细胞 (HSC).
结论:
- 针对相互连接的p53和c-MYC通道是CML的一种新型精准医学策略.
- 通过向酶独立途径,可以消除LSC,从而为CML提供潜在的治疗方法.
更多相关视频
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic...
